Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.

Samelis GF, Ekmektzoglou K, Tsiakou A, Giannakaki S, Konstadoulakis M.

Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1776-81. doi: 10.5754/hge10455. Epub 2011 Jul 15.

PMID:
21940348
2.

Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.

Ardavanis A, Kountourakis P, Karagiannis A, Doufexis D, Tzovaras AA, Rigatos G.

Anticancer Res. 2009 Dec;29(12):5211-7.

3.

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.

Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A.

Cancer Chemother Pharmacol. 2007 Jul;60(2):295-303. Epub 2006 Dec 6.

PMID:
17149608
4.

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.

Saif MW, Syrigos K, Penney R, Kaley K.

Anticancer Res. 2010 Jul;30(7):2905-9.

PMID:
20683031
5.

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.

Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I.

J Clin Oncol. 2009 Nov 20;27(33):5499-505. doi: 10.1200/JCO.2008.21.5384. Epub 2009 Oct 26.

PMID:
19858399
6.

A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.

Ignatiadis M, Polyzos A, Stathopoulos GP, Tselepatiotis E, Christophylakis C, Kalbakis K, Vamvakas L, Kotsakis A, Potamianou A, Georgoulias V.

Oncology. 2006;71(3-4):159-63. Epub 2007 Jul 17.

PMID:
17646699
7.

[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].

Takeda Y, Nakahira S, Katsura Y, Kagawa Y, Okishiro M, Takeno A, Sakisaka H, Suzuki R, Taniguchi H, Egawa C, Kato T, Tamura S.

Gan To Kagaku Ryoho. 2013 Nov;40(12):1884-6. Japanese.

PMID:
24393954
8.

Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.

Feliu J, Borrega P, León A, López-Gómez L, López M, Castro J, Belda-Iniesta C, Barriuso J, Martínez V, González-Barón M.

Cancer Chemother Pharmacol. 2011 Jan;67(1):215-21. doi: 10.1007/s00280-010-1472-0. Epub 2010 Oct 7.

PMID:
20927525
9.

Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.

Jacobs AD, Otero H, Picozzi VJ Jr, Aboulafia DM.

Cancer Invest. 2004;22(4):505-14.

PMID:
15565807
10.

[Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer].

Cheng YJ, Bai CM, Zhang ZJ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Aug;32(4):421-3. doi: 10.3881/j.issn.1000-503X.2010.04.013. Chinese.

11.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.

PMID:
17452677
12.

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP; European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

J Clin Oncol. 2005 Dec 20;23(36):9250-6.

PMID:
16361622
13.

Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.

Meyer F, Lueck A, Hribaschek A, Lippert H, Ridwelski K.

Chemotherapy. 2004 Dec;50(6):289-96. Epub 2004 Dec 8.

PMID:
15608445
14.

Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.

Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, Calley C, Loehrer PJ.

Oncology. 2003;65(3):218-23.

PMID:
14657595
15.

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.

Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7. doi: 10.1007/s00280-010-1257-5. Epub 2010 Feb 4.

PMID:
20130876
16.

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.

Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.

J Clin Oncol. 2007 Oct 20;25(30):4787-92.

PMID:
17947726
17.

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.

Watkins DJ, Starling N, Cunningham D, Thomas J, Webb J, Brown G, Barbachano Y, Oates J, Chau I.

Eur J Cancer. 2014 May;50(8):1422-9. doi: 10.1016/j.ejca.2014.02.003. Epub 2014 Mar 6.

PMID:
24613126
18.

Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.

Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ 3rd.

Ann Surg Oncol. 2011 Apr;18(4):1122-9. doi: 10.1245/s10434-010-1401-9. Epub 2010 Nov 23. Erratum in: Ann Surg Oncol. 2011 Dec;18 Suppl 3:S323.

PMID:
21104328
19.

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).

Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S.

Gut. 2013 May;62(5):751-9. doi: 10.1136/gutjnl-2012-302759. Epub 2012 Jul 7.

PMID:
22773551
20.

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

Boeck S, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler T, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Neugebauer S, Heinemann V.

Anticancer Drugs. 2010 Jan;21(1):94-100. doi: 10.1097/CAD.0b013e32833123ed.

PMID:
19770635

Supplemental Content

Support Center